COST-EFFECTIVENESS OF 13-VALENT VERSUS 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE AND NO VACCINATION IN THE CZECH NATIONAL VACCINATION PROGRAM

被引：1
|
作者：
Zigmond, J. [1 ]
Tichopad, A. [1 ]
Kolek, V [2 ]
Roberts, C. S. [3 ]
Hajek, P. [4 ]
机构：
[1] CEEOR Sro, Prague, Czech Republic
[2] Olomouc Univ Hosp, Olomouc, Czech Republic
[3] Pfizer, New York, NY USA
[4] Pfizer Sro, Prague, Czech Republic
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.331
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A73 / A74
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [2] Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Van Buynder, Paul
    Cripps, Allan W.
    [J]. VACCINE, 2019, 37 (24) : 3141 - 3141
  • [3] Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Chen, C.
    Beutels, P.
    Wood, J.
    Menzies, R.
    Maclntyre, C. R.
    McIntyre, P.
    Newall, A. T.
    [J]. VACCINE, 2018, 36 (42) : 6307 - 6313
  • [4] COST-EFFECTIVENESS OF 13-VALENT VERSUS 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE USE IN CROATIA NATIONAL VACCINATION PROGRAM
    Tichopad, A.
    Pecen, L.
    Roberts, C. S.
    Uglesic, L.
    Tesovic, G.
    Rogier, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A608 - A608
  • [5] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [6] A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
    Ngamprasertchai, Thundon
    Kositamongkol, Chayanis
    Lawpoolsri, Saranath
    Rattanaumpawan, Pinyo
    Luvira, Viravarn
    Chongtrakool, Piriyaporn
    Kaewkungwal, Jaranit
    Chokephaibulkit, Kulkanya
    Phisalprapa, Pochamana
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [7] Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
    Cho, Bo-Hyun
    Stoecker, Charles
    Link-Gelles, Ruth
    Moore, Matthew R.
    [J]. VACCINE, 2013, 31 (50) : 6011 - 6021
  • [8] Evaluation of appropriateness of vaccination procedures of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in a hospital setting
    Coleman, Paige
    Sears, Matthew
    Vaichys, Sabina
    Nemecek, Branden
    Guarascio, Anthony
    [J]. PHARMACOTHERAPY, 2015, 35 (11): : E305 - E305
  • [9] Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Newall, A. T.
    Wood, J. G.
    Chen, C.
    McIntyre, P.
    Beutels, P.
    [J]. VACCINE, 2019, 37 (52) : 7534 - 7534
  • [10] COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL VACCINATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPSV23) ON ADULT POPULATION IN SOUTH KOREA
    Park, D.
    Kang, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A788 - A788
12345